Announcement PDF ASX ANNOUNCEMENT 23 September 2026 Date of AGM and Closing Date for Director Nominations Biome Australia Limited (ASX:BIO) (Company) advises that, in accordance with ASX Listing Rule 3.13.1, its Annual General Meeting (AGM) will be held on Wednesday 25 November 2026. In accordance with clause 18.5(d) of the Company’s Constitution, the closing date for receipt of nominations for persons wishing to be considered for election as a Director is Monday 5 October 2026. Any nominations must be received at the Company’s registered office no later than 5.00pm (AEDST) on Monday 5 October 2026. Shareholders will be advised of further details regarding the AGM in a separate Notice of Meeting, which will be provided to shareholders in due course. The Notice of Meeting will also be available on the ASX Company Announcements Platform and on the Company’s website at www.biomeaustralia.com. –ENDS– Approved for release by the Biome Australia board of directors. Investor Hub Biome has launched a new interactive investor hub. To view a video presentation of this announcement, ask questions or sign up for future company updates, please visit the investor hub at https://investorhub.biomeaustralia.com/. About Biome Australia Limited Biome Australia develops, licences, commercialises and markets innovative, evidence-based live biotherapeutics (probiotics) and complementary medicines, many of which are supported by clinical research. Biome aims to improve health outcomes and quality of life, and make its products accessible to all. Incorporated in Australia in 2018, Biome distributes locally and abroad. In partnership with some of the world's leading organisations in microbiome research and development, Biome produced several unique live biotherapeutic (probiotic) products with innovative delivery technologies that improve their stability and efficacy to create its flagship range of complementary medicines: Activated Probiotics®. Supported by clinical research, including randomised double-blind placebo- controlled trials, Activated Probiotics and Activated Therapeutics help prevent and support the management of various health concerns, including low mood and sleep, bone health, iron malabsorption, mild eczema and IBS. Through practitioner-only distribution, Biome is committed to educating health professionals on the newfound systemic health effects of the gut microbiota, helping them to provide innovative, evidence-based natural medicines for the management of some of humanity's most prevalent and chronic health concerns. For more information visit: www.biomeaustralia.com Investor Relations Lauren Dwyer corporate@biomeaustralia.com (03) 9017 5800